HPE Now Powers New AI-Ready Supercomputer Set to Transform Environmental Forecasting in New Zealand




HPE Now Powers New AI-Ready Supercomputer Set to Transform Environmental Forecasting in New Zealand

HPE Cray XD2000 system now powers Earth Sciences New Zealand’s industry-leading ‘Supercomputing System for Advanced Weather Forecasting and Research’, accelerating environmental science and forecasting.

AUCKLAND, New Zealand–(BUSINESS WIRE)–HPE (NYSE:HPE) today announced that Earth Sciences New Zealand (formally NIWA) of Aotearoa (New Zealand) selected HPE Cray XD2000, purpose-built for AI and simulation workloads, to accelerate the organization’s environmental science and precision of meteorological forecasting.

The new system, named Cascade, replaces Earth Sciences New Zealand’s aging high performance computing (HPC) and delivers a threefold increase in computational power for researchers to run multiple AI-powered simulations simultaneously for more accurate weather predictions. The new system supports Earth Sciences New Zealand’s mission to strengthen the country’s resilience against weather and climate-related hazards, such as wildfires and flooding from heavy rainfall.

Cascade is powered by AMD 4th Gen EPYC processors and tightly coupled with HPE GreenLake for File Storage to deliver a highly performant, simplified storage environment and enable 19 petabytes of data to accelerate local research, supporting faster decision-making and more informed crisis management.

The Cascade system features direct liquid cooling (DLC) technology that minimizes energy use and water usage and efficiently cools the computational cluster, which was architected flexibly to allow future expansion. Furthermore, the electricity supplied to the CDC data centre, where Cascade is housed, is generated from 100% renewable sources.

“We’re thrilled to partner with Earth Sciences New Zealand on this groundbreaking initiative,” said Chris Weber, Vice President and Managing Director, South Pacific at HPE. “By delivering advanced HPC and AI capabilities, we’re empowering New Zealand’s leading climate and environmental researchers with the tools they need to drive scientific discovery and tackle some of the most pressing challenges of our time. Importantly, we’re able to maximise energy efficiency through direct liquid cooling and leverage renewable energy. This collaboration showcases the true potential of technology to make a meaningful impact, both locally and globally.”

In another milestone, Earth Sciences New Zealand’s Cascade is set to be the largest implementation in the Asia Pacific region of HPE GreenLake for File Storage, across both HPC and traditional enterprise computing. For Earth Sciences New Zealand, it represents a significant commitment to future-proof the country against the impacts of climate change and ensuring public safety for generations to come.

Based in Auckland, Earth Sciences New Zealand is the country’s leading provider of natural and environmental science services, internationally recognized for its cutting-edge research in climate, freshwater, geological resources, energy futures and marine science. As an island nation, New Zealand faces unique challenges from atmospheric rivers – narrow corridors in the atmosphere that carry large quantities of water vapor and are known to cause major rainfall events – which makes Earth Sciences New Zealand’s role in forecasting weather even more vital to support its national climate resilience.

“This upgrade with HPE Cray XD2000 marks a huge leap forward in our ability to understand and predict the environment around us,” says Dr. Jess Robertson, Chief Scientist – Advanced Technology at Earth Sciences New Zealand. “Enhancing scientific research with the advanced technology solutions gives us the tools to make smarter and safer decisions with confidence for New Zealand in a changing climate.”

Alongside its forecasting capabilities, Earth Sciences New Zealand also supports the country’s low-carbon economy and biodiversity protection, improving water quality, social equity, and regional development.

Partnering with HPE, Earth Sciences New Zealand is able to achieve unprecedented performance for its workloads, supercharging research data, processing and forecasting capabilities. Leveraging HPE’s extensive design and liquid cooling expertise, Cascade is purpose-built to operate at full capacity for longer, maximizing scalability and up-time. Cascade will also use real-time data to unlock an advanced weather forecasting technique referred to as nowcasting. Nowcasting uses AI to predict short-term, highly-localized weather rapidly, supporting the inclusion of solar and wind in high-frequency energy markets as well as emergency response to fires and extreme weather.

About Hewlett Packard Enterprise

HPE (NYSE: HPE) is a leader in essential enterprise technology, bringing together the power of AI, cloud and networking to help organisations achieve more. As pioneers of possibility, our innovation and expertise advance the way people live and work. We empower our customers across industries to optimise operational performance, transform data into foresight, and maximise their impact. Unlock your boldest ambitions with HPE. Discover more at www.hpe.com.

Contacts

Media Contact:
DEC PR on behalf of HPE

HPE@decpr.com.au

California Housing Finance Agency Welcomes Tony Sertich as Its New Executive Director




California Housing Finance Agency Welcomes Tony Sertich as Its New Executive Director

Sertich previously spent 14 years at CalHFA before serving in leadership positions for the State Controller and Department of Housing and Community Development

SACRAMENTO, Calif.–(BUSINESS WIRE)–Tony Sertich is the new Executive Director of the California Housing Finance Agency after he was appointed to the position by Governor Gavin Newsom on Friday.

Sertich, who most recently served as the Assistant Deputy Director over the Division of State Financial Assistance at the California Department of Housing and Community Development, is no stranger to CalHFA, serving as the Agency’s Financing Risk Manager, Director of Multifamily Programs and Director of Enterprise Risk Management and Compliance between 2005 and 2018.

Following his first stint at CalHFA, Sertich was State Controller Betty Yee’s top housing advisor from 2019 to 2022, a role that included serving as the Controller’s designee on the boards of the California Debt Limit Allocation Committee and the California Tax Credit Allocation Committee.

“Mr. Sertich knows CalHFA and, even more importantly, knows the state’s housing finance ecosystem from nearly every perspective,” said CalHFA Board Chair Jim Cervantes. “With CalHFA and its sister agencies moving into a new era under the umbrella of the California Housing and Homelessness Agency, Mr. Sertich’s experience and expertise will be invaluable.”

Sertich will take over as head of an organization that has a central role in helping the state address its housing policy goals. CalHFA helped 7,000 first-time and first-generation homebuyers in the last fiscal year and financed more than 2,700 affordable housing units with its lending and bond issuance in that same period. The Agency is also administering disaster mortgage relief and supporting housing counseling and recently received the highest credit rating in CalHFA’s 50-year history.

“With CalHFA’s financial strength expanding its ability to adjust to the dynamic housing market, and California’s housing finance system reorganization opening up even more ways to create much-needed housing opportunities, this Agency will be able to shine in the coming years,” Sertich said. “I’m excited to be part of CalHFA’s growth.”

“I look forward to Tony’s leadership as we continue our important work,” added Chief Deputy Director Rebecca Franklin, who has been CalHFA’s top executive for the last 10 months. “With CalHFA celebrating its 50^th anniversary this year, Tony is the perfect leader to guide the Agency into the next half century.”

The California Housing Finance Agency was created in 1975 with the goal of helping more Californians find a place to call home. CalHFA has helped more than 233,000 low- and moderate-income homebuyers with $43.5 billion in first mortgages and used $12.8 billion in financing for the construction and preservation of more than 85,000 rental housing units throughout the state. CalHFA is a self-supported state agency that doesn’t rely on taxpayer dollars for its operational costs but is currently administering various state and federal resources on behalf of the state through targeted programs. For more information on CalHFA programs, and how we are investing in diverse California communities, visit www.calhfa.ca.gov or call toll free at 877.9.CalHFA (877.922.5432).

Contacts

Chris Saur

Phone: 916.326.8604

Fax: 916.322.2345

csaur@calhfa.ca.gov
www.calhfa.ca.gov

California Housing Finance Agency Welcomes Tony Sertich as Its New Executive Director




California Housing Finance Agency Welcomes Tony Sertich as Its New Executive Director

Sertich previously spent 14 years at CalHFA before serving in leadership positions for the State Controller and Department of Housing and Community Development

SACRAMENTO, Calif.–(BUSINESS WIRE)–Tony Sertich is the new Executive Director of the California Housing Finance Agency after he was appointed to the position by Governor Gavin Newsom on Friday.

Sertich, who most recently served as the Assistant Deputy Director over the Division of State Financial Assistance at the California Department of Housing and Community Development, is no stranger to CalHFA, serving as the Agency’s Financing Risk Manager, Director of Multifamily Programs and Director of Enterprise Risk Management and Compliance between 2005 and 2018.

Following his first stint at CalHFA, Sertich was State Controller Betty Yee’s top housing advisor from 2019 to 2022, a role that included serving as the Controller’s designee on the boards of the California Debt Limit Allocation Committee and the California Tax Credit Allocation Committee.

“Mr. Sertich knows CalHFA and, even more importantly, knows the state’s housing finance ecosystem from nearly every perspective,” said CalHFA Board Chair Jim Cervantes. “With CalHFA and its sister agencies moving into a new era under the umbrella of the California Housing and Homelessness Agency, Mr. Sertich’s experience and expertise will be invaluable.”

Sertich will take over as head of an organization that has a central role in helping the state address its housing policy goals. CalHFA helped 7,000 first-time and first-generation homebuyers in the last fiscal year and financed more than 2,700 affordable housing units with its lending and bond issuance in that same period. The Agency is also administering disaster mortgage relief and supporting housing counseling and recently received the highest credit rating in CalHFA’s 50-year history.

“With CalHFA’s financial strength expanding its ability to adjust to the dynamic housing market, and California’s housing finance system reorganization opening up even more ways to create much-needed housing opportunities, this Agency will be able to shine in the coming years,” Sertich said. “I’m excited to be part of CalHFA’s growth.”

“I look forward to Tony’s leadership as we continue our important work,” added Chief Deputy Director Rebecca Franklin, who has been CalHFA’s top executive for the last 10 months. “With CalHFA celebrating its 50^th anniversary this year, Tony is the perfect leader to guide the Agency into the next half century.”

The California Housing Finance Agency was created in 1975 with the goal of helping more Californians find a place to call home. CalHFA has helped more than 233,000 low- and moderate-income homebuyers with $43.5 billion in first mortgages and used $12.8 billion in financing for the construction and preservation of more than 85,000 rental housing units throughout the state. CalHFA is a self-supported state agency that doesn’t rely on taxpayer dollars for its operational costs but is currently administering various state and federal resources on behalf of the state through targeted programs. For more information on CalHFA programs, and how we are investing in diverse California communities, visit www.calhfa.ca.gov or call toll free at 877.9.CalHFA (877.922.5432).

Contacts

Chris Saur

Phone: 916.326.8604

Fax: 916.322.2345

csaur@calhfa.ca.gov
www.calhfa.ca.gov

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event




Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25^th edition of the European Midcap Event being held from September 30 to October 1, 2025 in Paris, France.

The European Midcap Event is a key gathering that brings together institutional investors and listed companies to foster strategic meetings and financing opportunities. This flagship event provides a unique platform to engage with the European financial community.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

For additional information, please contact:
Innate Pharma
Stéphanie Cornen

stephanie.cornen@innate-pharma.fr

Investor Relations
investors@innate-pharma.fr

Medias
communication@innate-pharma.fr

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event




Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25^th edition of the European Midcap Event being held from September 30 to October 1, 2025 in Paris, France.

The European Midcap Event is a key gathering that brings together institutional investors and listed companies to foster strategic meetings and financing opportunities. This flagship event provides a unique platform to engage with the European financial community.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

For additional information, please contact:
Innate Pharma
Stéphanie Cornen

stephanie.cornen@innate-pharma.fr

Investor Relations
investors@innate-pharma.fr

Medias
communication@innate-pharma.fr

Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial




Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial

IRVINE, Calif.–(BUSINESS WIRE)–#clinicaltrials—Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas.

Diality is conducting the PRESCRIBE Diality trial under an Investigational Device Exemption (IDE) to evaluate a home use indication for the Moda-flx Hemodialysis System. The Moda-flx Hemodialysis System received U.S. Food and Drug Administration (FDA) clearance for use in professional care settings in August 2024.

”Diality’s Moda-flx Hemodialysis System is unique in its ability to offer an integrated reverse osmosis (RO) system combined with dialysis flow rates (Qd) up to 600 mL/min. Moda-flx addresses the gaps that exist between conventional in-center dialysis and current home hemodialysis systems. Those gaps often force clinicians to compromise elements of dialysis care due to the limitations of their technology,” said Diality CEO Dr. Osman Khawar. “We are fortunate to work with clinical partners like aQua Dialysis who are committed to supporting clinical research and home hemodialysis, and improving the dialysis experience for both patients and clinicians.”

The Moda–flx Hemodialysis System is designed to empower kidney care professionals with a wide range of variable flow rates, integrated reverse osmosis water filtration, and an intuitive, easy-to-use graphical user interface. It provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated system. The platform’s compact footprint and mobility also enable seamless integration and transportation between dialysis care settings.

“We are excited to partner with Diality in this clinical trial with the objective of providing clinicians, patients and their caregivers improved technology options to positively impact their day to day lives,” said Ivan Ramirez, CEO of aQua Research Institute and Dialysis.

About Diality

Diality is a medical device company focused on developing solutions to improve lives impacted by kidney disease. The Moda-flx Hemodialysis System is a user-friendly, mobile, and connected hemodialysis platform designed to maximize clinical flexibility by combining prescription capabilities of in-center systems with the ease-of-use of next generation hemodialysis devices. Please visit www.diality.com or find us on LinkedIn to learn more about Diality and The Moda-flx Hemodialysis System.

Contacts

MEDIA CONTACT:

Sam Choinski

Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058

Virtus Investment Partners Reports Preliminary August 31, 2025 Assets Under Management




Virtus Investment Partners Reports Preliminary August 31, 2025 Assets Under Management

HARTFORD, Conn.–(BUSINESS WIRE)–Virtus Investment Partners, Inc. (NYSE: VRTS) today reported preliminary assets under management (AUM) of $170.6 billion and other fee earning assets of $1.8 billion for total client assets of $172.4 billion as of August 31, 2025. The change in AUM from July 31, 2025 reflects net outflows in institutional accounts, U.S. retail funds, and retail separate accounts, offset by market performance and positive net flows in exchange-traded funds.

About Virtus Investment Partners, Inc.

Virtus Investment Partners (NYSE: VRTS) is a distinctive partnership of boutique investment managers singularly committed to the long-term success of individual and institutional investors. We provide investment products and services from our investment managers, each with a distinct investment style and autonomous investment process, as well as select subadvisers. Investment solutions are available across multiple disciplines and product types to meet a wide array of investor needs. Additional information about our firm, investment partners, and strategies is available at virtus.com.

Contacts

Investor Relations Contact:
Sean Rourke

(860) 263-4709

sean.rourke@virtus.com

Media Relations Contact:
Laura Parsons

(860) 503-1382

laura.parsons@virtus.com

IonQ Leaders to Present at 2025 Quantum World Congress




IonQ Leaders to Present at 2025 Quantum World Congress

IonQ to highlight enterprise use cases and global momentum at leading quantum event

COLLEGE PARK, Md.–(BUSINESS WIRE)–IonQ (NYSE: IONQ), the leader in the quantum computing and networking industries, will participate in the globally influential 2025 Quantum World Congress, taking place September 16-18 at Capital One Hall in Tysons, Virginia. The annual event brings together global quantum experts and visionaries to advance innovation across quantum computing, research, academia, software development, legislative and policy areas.

Beyond livestreaming a keynote speech at the global event, IonQ executives will join programming across the three-day meeting, presenting updates on the company’s global partnership momentum, and strategic vision for the quantum industry. As part of four sessions, the company will offer insights into the evolving quantum ecosystem, from scaling real-world applications to building collaborative partnerships across academia, enterprise, and government:

• Industry Perspective Keynote, presented by Niccolo de Masi, Chairman and CEO at IonQ – hosted by QWC – 11:00 -11:20 a.m. ET on September 17
• The Power of Partnerships: Advancing Quantum Technologies Towards Commercialization, IonQ panelist, Rima Alameddine, Chief Revenue Officer – hosted by EPB – 1:00 -1:30 p.m. ET on September 17
• Building Quantum Ecosystems in Emerging Markets, IonQ Panelist, Ryan Harring, Senior Relationship Manager – hosted by EPB – 4:00 – 4:30 p.m. ET on September 17
• Quantum & Arts: Bridging Worlds to Deliver Accessibility, Inspiration and Creativity, IonQ panelist, Margaret Arakawa, Chief Marketing Officer – hosted by University of Maryland – 4:30 – 5:00 p.m. ET on September 17

Now in its fourth year, Quantum World Congress is organized by Connected DMV in collaboration with regional stakeholders and global sponsors. IonQ’s presence at the event follows a period of rapid growth and global expansion, including a recently expanded patent portfolio accelerating the company’s timeline to commercial quantum advantage, strategic partnerships across Europe and Asia with organizations like KISTI, Emergence Quantum, and Einride, and continued advances in commercial-grade quantum computing and networking.

For more information about IonQ’s technology and partnerships, visit www.ionq.com.

About IonQ

IonQ, Inc. [NYSE: IONQ] is the leading commercial quantum computing and quantum networking company, delivering high-performance systems aimed at solving the world’s most complex problems. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results.

The company is accelerating its technology roadmap and intends to deliver the world’s most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ’s advancements in quantum networking also position the company as a leader in building the quantum internet.

The company’s innovative technology and rapid growth were recognized in Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, and Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including but not limited to the terms “accelerating,” “advancements,” “building,” “delivering,” “driving,” “growth,” “intends,” and other similar expressions, are intended to identify forward-looking statements. These statements include those related to the IonQ’s quantum computing capabilities and plans. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ’s inability to attract and retain key personnel; or IonQ’s ability to deliver, and customers’ ability to generate, value from IonQ’s offerings. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s filings with the U.S. Securities and Exchange Commission, including but not limited to the Company’s most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

Contacts

IonQ Media contact:
press@ionq.co

IonQ Investor Contact:
investors@ionq.co

Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial




Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial

IRVINE, Calif.–(BUSINESS WIRE)–#clinicaltrials—Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas.

Diality is conducting the PRESCRIBE Diality trial under an Investigational Device Exemption (IDE) to evaluate a home use indication for the Moda-flx Hemodialysis System. The Moda-flx Hemodialysis System received U.S. Food and Drug Administration (FDA) clearance for use in professional care settings in August 2024.

”Diality’s Moda-flx Hemodialysis System is unique in its ability to offer an integrated reverse osmosis (RO) system combined with dialysis flow rates (Qd) up to 600 mL/min. Moda-flx addresses the gaps that exist between conventional in-center dialysis and current home hemodialysis systems. Those gaps often force clinicians to compromise elements of dialysis care due to the limitations of their technology,” said Diality CEO Dr. Osman Khawar. “We are fortunate to work with clinical partners like aQua Dialysis who are committed to supporting clinical research and home hemodialysis, and improving the dialysis experience for both patients and clinicians.”

The Moda–flx Hemodialysis System is designed to empower kidney care professionals with a wide range of variable flow rates, integrated reverse osmosis water filtration, and an intuitive, easy-to-use graphical user interface. It provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated system. The platform’s compact footprint and mobility also enable seamless integration and transportation between dialysis care settings.

“We are excited to partner with Diality in this clinical trial with the objective of providing clinicians, patients and their caregivers improved technology options to positively impact their day to day lives,” said Ivan Ramirez, CEO of aQua Research Institute and Dialysis.

About Diality

Diality is a medical device company focused on developing solutions to improve lives impacted by kidney disease. The Moda-flx Hemodialysis System is a user-friendly, mobile, and connected hemodialysis platform designed to maximize clinical flexibility by combining prescription capabilities of in-center systems with the ease-of-use of next generation hemodialysis devices. Please visit www.diality.com or find us on LinkedIn to learn more about Diality and The Moda-flx Hemodialysis System.

Contacts

MEDIA CONTACT:

Sam Choinski

Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058

Perion Launches “SODA” – Next Generation AI-Powered Supply-Side Technology for Web and DOOH Designed to Increase Revenue for Publishers, and Reduce Waste for Advertisers




Perion Launches “SODA” – Next Generation AI-Powered Supply-Side Technology for Web and DOOH Designed to Increase Revenue for Publishers, and Reduce Waste for Advertisers

Already Adopted by Mediatransports, SODA Enables Publishers to Maximize Revenue through AI-Modeling Optimization

NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)–#tech—Perion Network Ltd. (NASDAQ & TASE: PERI), a leader in advanced technology solving for the complexities of modern advertising, today announced the launch of SODA (Supply Optimization & Demand Amplification), an AI-powered suite of solutions for publishers, featuring a next-generation AI algorithm for Supply Path Optimization (SPO) designed to maximize efficiency and monetization across every ad impression.

With SODA, Perion introduces a new standard in Supply Path Optimization. Powered by real-time mediation, direct integration with Perion’s demand-side intelligence, and sustainability logic, SODA delivers SPO 2.0, a breakthrough for digital publishers seeking financial performance, efficiency, and environmental responsibility.

Unlocking New Value on the Supply Side

SODA integrates seamlessly into any website and DOOH screen, introducing a suite of capabilities:

• Smart Mediation Layer: SODA evaluates all incoming bid requests from Demand-Side Platforms (DSPs) and Supply-Side Platforms (SSPs), selecting only the top-performing paths to ensure maximum yield for publishers.
• Demand-Side Synergy with Perion’s Algo: Running in parallel with Perion’s demand-side Algo, SODA enables enhanced feedback loops, constantly identifying and rewarding high-performing inventory with increased demand and higher CPMs.
• Revenue Growth & Retention: Access to Perion’s multiformat, high-impact demand drives higher CPMs, more monetization opportunities, and long-term publisher stickiness.
• Transparency Into Supply: Enabling publishers to gain insight into SSP performance to inform decisions on whether there’s a need to adjust the mix of supply partners.
• Optimized Site Performance and Efficiency: Website users enjoy quicker load times for websites and relevant ad experiences, optimizing every impression’s journey by selecting the most efficient ad paths.

“In a market saturated with inefficiencies and growing concern over unrealized ad revenues, SODA is a breakthrough,” said Tal Jacobson, CEO of Perion. “It’s not just a supply-side solution; it’s a redefinition of how supply and demand should interact. With SODA, we’re giving publishers the tools to optimize revenue responsibly, at scale, and with measurable impact.”

SODA is now available for integration for selected premium publishers, and is already in use by Mediatransports, a leader in Digital-Out-Of-Home advertising in France, leveraging its AI-powered capabilities to optimize DOOH campaigns in transport environments, such as train stations and subways.

“The Digital-Out-Of-Home landscape is evolving rapidly, and smart, AI-driven solutions are critical. The ability of Perion’s AI-suite SODA to optimize supply paths and maximize monetization is a game-changer for our business, ensuring that we deliver on our promise of performance and efficiency for our advertisers,” said Valérie Decamp, CEO of Mediatransports.

As part of Perion’s broader vision to unify performance and sustainability across the digital advertising ecosystem, SODA complements Perion’s existing AI innovations, such as Wave, SORT, and GreenBids (Now Perion Algo).

About Perion

Perion is helping agencies, brands and retailers get better results with their marketing investments by providing advanced technology across digital channels. Through the Perion One platform, we are making digital advertising more effective by building solutions that continuously adapt to connect the dots between data, creative and channels.

For more information, visit Perion’s website at www.perion.com.

Forward Looking Statements

This press release contains historical information and forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the safe- harbor provisions of the Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of Perion. The words “will,” “believe,” “expect,” “intend,” “plan,” “should,” “estimate” and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of Perion with respect to future events and are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. Many factors could cause the actual results, performance or achievements of Perion to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, but not limited to, political, economic and other developments (including the current war between Israel and Hamas and other armed groups in the region), the failure to realize the anticipated benefits of companies and businesses we acquired and may acquire in the future, risks entailed in integrating the companies and businesses we acquire, including employee retention and customer acceptance, the risk that such transactions will divert management and other resources from the ongoing operations of the business or otherwise disrupt the conduct of those businesses, and general risks associated with the business of Perion including, the transformation in our strategy, intended to unify our business units under the Perion brand (Perion One), intense and frequent changes in the markets in which the businesses operate and in general economic and business conditions (including the fluctuation of our share price), loss of key customers or of other partners that are material to our business, the outcome of any pending or future proceedings against Perion, data breaches, cyber-attacks and other similar incidents, unpredictable sales cycles, competitive pressures, market acceptance of new products and of the Perion One strategy, changes in applicable laws and regulations as well as industry self-regulation, negative or unexpected tax consequences, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, whether referenced or not referenced in this press release. We urge you to consider those factors, together with the other risks and uncertainties described in our most recent Annual Report on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (SEC) on March 25, 2025, and our other reports filed with the SEC, in evaluating our forward-looking statements and other risks and uncertainties that may affect Perion and its results of operations. Perion does not assume any obligation to update these forward-looking statements.

Contacts

Perion Network Ltd.

Dudi Musler, VP of Investor Relations

+972 (54) 7876785

dudim@perion.com